HVNI vs NIPPV in Type 2 Respiratory Failure

NANot yet recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Respiratory FailureHypoxiaHypercapnia
Interventions
DEVICE

Vapotherm high velocity therapy (HVT) 2.0 (Vapotherm, Inc, Exeter, NH)

Oxygen therapy will be given via the Vapotherm high velocity therapy (HVT) 2.0 (Vapotherm, Inc, Exeter, NH) using a small-bore cannula, with a flow rate of up to 45 L/min, starting temperature of 37oC and FiO2 of up to 1.0.

DEVICE

Respironics Vision V60

Ventilation will be performed with the Respironics Vision V60 (Philips Healthcare, Murrysville, PA) using an oronasal mask of appropriate size, with FiO2 (up to 1.0), inspiratory (IPAP 12 to 20 cmH2O) and expiratory (EPAP 5 to 10 cm H2O) pressures titrated to alleviate patient's respiratory distress.

All Listed Sponsors
collaborator

Vapotherm, Inc.

INDUSTRY

lead

National University Hospital, Singapore

OTHER

NCT07065656 - HVNI vs NIPPV in Type 2 Respiratory Failure | Biotech Hunter | Biotech Hunter